Insider Selling: Progyny (NASDAQ:PGNY) CFO Sells $211,012.50 in Stock

Progyny, Inc. (NASDAQ:PGNY) CFO Mark Livingston sold 8,275 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $25.50, for a total transaction of $211,012.50. Following the transaction, the chief financial officer directly owned 79,063 shares in the company, valued at approximately $2,016,106.50. This trade represents a 9.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Stock Up 0.8%

Shares of PGNY stock opened at $24.88 on Friday. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of 32.31, a PEG ratio of 1.32 and a beta of 0.91. The company’s 50 day moving average is $19.06 and its 200 day moving average is $22.03. Progyny, Inc. has a 52-week low of $16.10 and a 52-week high of $28.75.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.03. The business had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.47 million. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The business’s revenue for the quarter was down 26.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Analysts anticipate that Progyny, Inc. will post 1.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Progyny

Large investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd acquired a new position in shares of Progyny in the 4th quarter worth approximately $25,000. Federated Hermes Inc. lifted its holdings in shares of Progyny by 147.3% in the 3rd quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock worth $30,000 after acquiring an additional 819 shares during the last quarter. Hantz Financial Services Inc. lifted its holdings in shares of Progyny by 79.4% in the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after acquiring an additional 742 shares during the last quarter. Covestor Ltd lifted its holdings in shares of Progyny by 164.9% in the 3rd quarter. Covestor Ltd now owns 2,609 shares of the company’s stock worth $56,000 after acquiring an additional 1,624 shares during the last quarter. Finally, Quarry LP lifted its holdings in shares of Progyny by 2,004.1% in the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock worth $77,000 after acquiring an additional 3,427 shares during the last quarter. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on PGNY shares. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, April 18th. Citigroup reaffirmed an “outperform” rating on shares of Progyny in a research note on Monday, May 11th. Barclays upped their price objective on shares of Progyny from $23.00 to $27.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Jefferies Financial Group reaffirmed a “buy” rating and set a $30.00 price objective on shares of Progyny in a research note on Friday, March 6th. Finally, Truist Financial upped their price objective on shares of Progyny from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Progyny currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.55.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.